Patents by Inventor Richard M. Torczynski

Richard M. Torczynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6242204
    Abstract: Hybridomas secreting monoclonal antibodies specific for an epitope found in the amino acids of LCGA associated with non-small cell lung carcinoma protein have been found. The monoclonal antibodies produced by these hybridomas can be used in in vivo and in vitro clinical diagnosis of non-small cell lung carcinoma and ovarian carcinoma and as target selective carriers for various anti-tumor agents and radioimaging agents.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: June 5, 2001
    Assignee: Cytoclonal Pharmaceutics, Inc.
    Inventors: Richard M. Torczynski, Arthur P. Bollon
  • Patent number: 6117981
    Abstract: Hybridomas secreting monoclonal antibodies specific for an epitope found in the amino acids of LCGA associated with non-small cell lung carcinoma protein have been found. The monoclonal antibodies produced by these hybridomas can be used in in vivo and in vitro clinical diagnosis of non-small cell lung carcinoma and ovarian carcinoma and as target selective carriers for various anti-tumor agents and radioimaging agents.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: September 12, 2000
    Assignee: Cytoclonal Pharmaceutics, Inc.
    Inventors: Richard M. Torczynski, Arthur P. Bollon
  • Patent number: 5773579
    Abstract: The present invention discloses an isolated and purified nucleic acid sequence and corresponding amino acid sequence to a novel protein specific for human lung cancer cells. This gene is expressed at a much higher level in these cells than in normal lung cells, other normal tissues and other tumor cell lines tested. Also disclosed are three additional recombinant forms of this gene and protein, in the first two cases a membrane spanning region is removed and in the third case an amino acid is changed by in vitro mutagenesis.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: June 30, 1998
    Assignee: Cytoclonal Pharmaceutics, Inc.
    Inventors: Richard M. Torczynski, Arthur P. Bollon
  • Patent number: 5589579
    Abstract: The present invention discloses an isolated and purified nucleic acid sequence and corresponding amino acid sequence to a novel protein specific for human lung cancer cells. This gene is expressed at a much higher level in these cells than in normal lung, other normal tissues and other tumor cell lines tested. Also disclosed are two additional recombinant forms of this gene and protein, in the first case a membrane spanning region is removed and in the second case an amino acid is changed by in vitro mutagenesis. Also disclosed are nucleic acid probes for the detection of lung cancer cells from tissue biopsy and body fluids such as serum, sputum and bronchial washings. A method for expressing the antigen in a host cell and its subsequent use as an immunogen in antibody production for test applications is described. An ELISA test to measure shed antigen present in patient samples as well as an enzyme test to measure activity in specimens also is described.
    Type: Grant
    Filed: July 19, 1994
    Date of Patent: December 31, 1996
    Assignee: Cytoclonal Pharmaceutics, Inc.
    Inventors: Richard M. Torczynski, Arthur P. Bollon